Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease

Summary

The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for Alzheimer's disease.

Timeline

Start

2007-11

Primary completion

2009-06

Completion

—

Outcome

Missed primary endpoint

paper No dose demonstrated statistically significant improvement over placebo on ADAS-Cog or any secondary endpoint. PMID 25973909 ↗

Publications

• Lenz RA, Pritchett YL, Berry SM, Llano DA, Han S, Berry DA, Sadowsky CH, Abi-Saab WM, Saltarelli MD. Adaptive, dose-finding phase 2 trial evaluating the safety and efficacy of ABT-089 in mild to moderate Alzheimer disease. Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):192-9. doi: 10.1097/WAD.0000000000000093.

Drugs

Indications